Member Info for CrustyPete

News tomorrow?

Only my opinion Van Van but, personally, I place a lot more value on that FDA approval and fast track than you appear to. Scancell has had tremendous potential for some considerable time but there have always been some significant "barriers" to their realising that potential. That FDA approval (and to a lesser extent the awaited UK and European equivalent) signals the removal of the biggest single hurdle that has stood in their way. Now, subject to funding those trials, which, for many, including me, would suggest is only a question of time. Phil L'H recently stated that the search for funding was progressing "at pace". Once that has been achieved there is absolutely no reason that SCLP will not, at long last, reach, or even exceed their advisers current forecast of 35p per share - an estimate, which, as roses and others have pointed out is due a significant upward revision - and that revision will happen as soon as funding is confirmed.

Above all of the above there is also significant speculation that, with FDA approval Scancell will be in the cross hairs of many a large US Pharma company that would love to add the Scancell portfolio to their own. Similar companies have recently been acquired for valuations many times that of Scancell's current Market Cap.

So, in short and as EE recently predicted there is a scramble for investors to get in ahead of the action; to wait for funding and NAV upgrades will be too late, let alone a potential Buyout.

Dropped back just before the close; it will be interesting to see if there are any delayed trades being reported after COP.

Let's hope tomorrow is just as good a day. Maybe some news? Here's hoping.

GLA

Blimey, serious momentum now. 19.0p BID.

Well there's a vote of confidence...... :0(

News has been expected for a little while and on a number of fronts, though with no specified target dates, not officially late; milestone payments from Genmab, update on Modi trials, European and UK approvals for stage 3 trails for 1SCIB1+ and, though certainly not overdue, funding for Stage 3 trails for iSCIB1+ in the US.

All, soon to be with us.

Most resistance points now behind us. See below.

https://www.barchart.com/stocks/quotes/SCLP.LN/cheat-sheet

There was a delayed sell of 291,000 at 17.95p but , in the main, predominantly Buys. That 2 year high might provide some resistance but after that the sky's the limit. ;0)

MM's surely now short of shares. It will be interesting to see what underhand tactics they employ to get some stock in. A 5050 UT trade at 17.80p?!

Indeed researcher, as you say, some of that value is within touching distance. So close in fact that it is a moot point as to whether we would be better funding the Stage 3 trials ourselves and thereby extracting optimal value from 1SCIB1+. After all what is another 18+ months after all this time?

COS will then be negligible (For SCIB) and our other platforms will be far closer to optimising/realising their potential and, hence, value.

18.20p for smaller parcels.

And MM's are bidding 18.0p for up to 200k - 17.60p for 500k.

Yes chester the momentum appears to be gathering pace and supports all the positive speculation regarding a sale or similar. I am sure that no-one would object to that. ;0)

Though the sp rise may simply be down to recognition that Scancell has been undervalued for ages. And not a moment to soon if so.

If the MC rises above £200m it would but the Company in the cross hairs of a large number of Funds and Investment Managers that are precluded from investing in "micro-cap" Companies.

Apologies roses if I am misinformed or incorrect. It certainly wasn't deliberate and, frankly, even if wrong do not see that in any way suggesting negative or "joyless" connotations, indeed as I suggested, in the longer term any actually be beneficial for shareholder value. But hey, knock yourself out, see if I care.

I would agree Pepe and have mentioned before that our advisers preference is for Scancell to "go it alone" which will , of course require the company to fund the Stage lll trials themselves. What is more a partnership may not provide much more, in the first instance, than sufficient capital to fund those same trials.

So whilst I am sure that we would all love to see a sale of all or part of Scancell there are other alternatives that may not provide as large a short term pay day but which might offer greater value to shareholders in the longer term.

In either event patience is required and that "pay day" is surely a question of "when" and not "if". As indeed are the beneficial outcomes for patients.

The MM's are getting a bit if stock back at 17.0p and just below. No great surprise and it will surely dry up fairly quickly.

MM's currently paying 17.0p for 100k. 16.90p for 200k and 16.65p for 300k. (At II).

@Marcus and anyone. I question the logic behind the statement "But it noted it has not yet upgraded its success probability to the phase III level of 60%, keeping it at 40%, until the financing route for the pivotal trial is secured."

Surely the question of "funding" is not an "if" but a "when" and a "how" - it is a given, so why is the COS contingent on it? If all else fails SCLP could go to the market - AIM, or perhaps NASDAQ (timing not withstanding).

They are not going to undersell it PC. It is not in their interests.

PC, PVE want a Farm-In partner! They will pump it as much as they can...... they will get paid on the results.